Provectus Biopharmaceuticals Inc
OTC:PVCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Provectus Biopharmaceuticals Inc
Accumulated Depreciation
Provectus Biopharmaceuticals Inc
Accumulated Depreciation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Provectus Biopharmaceuticals Inc
OTC:PVCT
|
Accumulated Depreciation
-$120k
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
12%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Accumulated Depreciation
-$31.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accumulated Depreciation
-$5.3B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-2%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Accumulated Depreciation
-$17.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Accumulated Depreciation
-$21.9B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Accumulated Depreciation
-$12.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-4%
|
|
Provectus Biopharmaceuticals Inc
Glance View
Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company. The company is headquartered in Knoxville, Tennessee and currently employs 4 full-time employees. The company went IPO on 2000-04-07. The firm is focused on developing immunotherapy medicines for different diseases, based on a family of small molecules called halogenated xanthenes (HXs). Its lead HX molecule, rose bengal sodium (RBS). Its product pipeline includes PV-10 and PH-10. Its PV-10 is an investigational cancer immunotherapy administered by intralesional (IL) injection and an injectable formulation of cGMP (current Good Manufacturing Practice) RBS, is undergoing clinical study for adult solid tumor cancers, such as melanoma and gastrointestinal (GI) tumors. PH-10 is an investigational immuno-dermatology agent administered as a topical gel and formulation of cGMP RBS, is undergoing monotherapy clinical study and preclinical study of combination therapy with approved drugs for inflammatory dermatoses. Its ongoing pre-clinical studies in other areas include hematology, virology, microbiology, ophthalmology, and animal health.
See Also
What is Provectus Biopharmaceuticals Inc's Accumulated Depreciation?
Accumulated Depreciation
-120k
USD
Based on the financial report for Dec 31, 2025, Provectus Biopharmaceuticals Inc's Accumulated Depreciation amounts to -120k USD.
What is Provectus Biopharmaceuticals Inc's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 10Y
12%
Over the last year, the Accumulated Depreciation growth was -2%. The average annual Accumulated Depreciation growth rates for Provectus Biopharmaceuticals Inc have been -6% over the past three years , -8% over the past five years , and 12% over the past ten years .
